News
13h
Zacks Investment Research on MSNWill Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results